TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8915784

Group type: EXPERIMENTAL
Intervention: Distal radius bone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Iliac crest bone
Number of subjects: 18
Study: 1920461

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6763357

Group type: EXPERIMENTAL
Intervention: Albendazole 400 mg (Group A)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Albendazole 600 mg (Group B)
Number of subjects: 35
Study: 30794304

Group type: EXPERIMENTAL
Intervention: 600 mg per day of DHA
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo (half soy and half corn oil)
Number of subjects: 350
Study: 28130552

Group type: EXPERIMENTAL
Intervention: MSDK (melatonin, strontium (citrate), vitamin D3 and vitamin K2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MSDK
Number of subjects: 100
Study: 25351284

Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75%
Number of subjects: 319
Study: 24188512

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy for PTSD, 10 weekly sessions
Number of subjects: 64
Study: 23064072

Group type: EXPERIMENTAL
Intervention: Low-dose FP chemotherapy (continuous 5-FU 500mg/day with intermittent CDDP 10mg/day)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Low-dose FP chemotherapy (same regimen resumed after recurrence)
Number of subjects: 1
Study: 18634707

Group type: EXPERIMENTAL
Intervention: Combination of lactitol and Lactobacillus acidophilus NCFM, consumed twice daily for 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of lactitol and Lactobacillus acidophilus NCFM
Number of subjects: 0
Study: 17497139

Group type: EXPERIMENTAL
Intervention: High-dose venlafaxine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose sertraline
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose citalopram
Number of subjects: 24
Study: 15055667

Group type: EXPERIMENTAL
Intervention: Etching time of 5 seconds
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Etching time of 15 seconds
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Etching time of 30 seconds
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Etching time of 60 seconds
Number of subjects: 39
Study: 11860668

Group type: EXPERIMENTAL
Intervention: Integrated Care
Number of subjects: 84

Group type: COMPARATOR
Intervention: Rational Rehabilitation
Number of subjects: 84
Study: 10067020

Group type: EXPERIMENTAL
Intervention: Band ligation (BL)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sclerotherapy (Scl)
Number of subjects: 58
Study: 9618066

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 182
Study: 2205379

Group type: EXPERIMENTAL
Intervention: Intraperitoneal recombinant interleukin‐2 (rIL‐2) and lymphokine‐activated killer cells (LAK)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraperitoneal rIL‐2 at 8 X 10(6) units/m2/dose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraperitoneal rIL‐2 and LAK infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraperitoneal rIL‐2 infusion
Number of subjects: 10
Study: 523778

Group type: EXPERIMENTAL
Intervention: Bismuth protein complex (Bicitropeptide)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Antacid
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 30653413

Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 23
Study: 28242860

Group type: EXPERIMENTAL
Intervention: Sleep intervention (sleep and combination)
Number of subjects: 802

Group type: COMPARATOR
Intervention: FAB intervention (FAB and combination)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 802
Study: 26066705

Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Single-hormone artificial pancreas
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Conventional insulin pump therapy
Number of subjects: 33
Study: 23386157

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic appendectomy (SILA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Open Appendectomy (OA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard 3-port Laparoscopic Appendectomy (SLA)
Number of subjects: 75
Study: 21131632

Group type: EXPERIMENTAL
Intervention: Full anonymity
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Quasi anonymity
Number of subjects: 150

Group type: COMPARATOR
Intervention: Traditional confidentiality
Number of subjects: 150
Study: 19158369

Group type: EXPERIMENTAL
Intervention: Fermagate 1 g three times daily
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Fermagate 2 g three times daily
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 17359569

Group type: EXPERIMENTAL
Intervention: Home health care through a combination of traditional face‐to‐face and telemedicine visits (n = 83)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Conventional home care (n = 78)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Home telecare services
Number of subjects: 161
Study: 14558885

Group type: EXPERIMENTAL
Intervention: Early enteral diet with glutamine and probiotics (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (early enteral diet without glutamine and probiotics, n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 11491008

Group type: EXPERIMENTAL
Intervention: Mefloquine (10 mg/kg at 0 h, then 5 mg/kg at 6 h)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Artesunate (4 mg/kg on day 0, then 2 mg/kg on day 1 to 4)
Number of subjects: 50

Group type: COMPARATOR
Intervention: In vitro sensitivity tests for chloroquine
Number of subjects: 50

Group type: COMPARATOR
Intervention: In vitro sensitivity tests for mefloquine
Number of subjects: 50

Group type: COMPARATOR
Intervention: In vitro sensitivity tests for quinine
Number of subjects: 50

Group type: COMPARATOR
Intervention: In vitro sensitivity tests for artemisinin
Number of subjects: 50
Study: 9875997

Group type: EXPERIMENTAL
Intervention: Virtual reality sigmoidoscopy simulator training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no simulator training)
Number of subjects: 10
Study: 7979523

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (40 mg/day)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Oxandrolone (2.5 mg/day)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 33
Study: 3261651

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 268

Group type: COMPARATOR
Intervention: Surgical treatment (ungrafted arteries)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Surgical treatment (grafted arteries)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Surgical treatment (closed grafts)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Grafted arteries (patent vs closed)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Coronary artery treatment (regardless of type)
Number of subjects: 268
Study: 31144431

Group type: EXPERIMENTAL
Intervention: Triple therapy with dapagliflozin 5 mg/d plus saxagliptin 5 mg/d added to metformin
Number of subjects: 883

Group type: COMPARATOR
Intervention: Dual therapy with dapagliflozin added to metformin
Number of subjects: 883

Group type: COMPARATOR
Intervention: Dual therapy with saxagliptin added to metformin
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 883

Group type: COMPARATOR
Intervention: Dual therapy with dapagliflozin
Number of subjects: 883

Group type: COMPARATOR
Intervention: Dual therapy with saxagliptin
Number of subjects: 883
Study: 29110216

Group type: EXPERIMENTAL
Intervention: Conditional economic incentives (CEIs)
Number of subjects: 227
Study: 26656981

Group type: EXPERIMENTAL
Intervention: Integrative treatment including moxibustion therapy conducted twice a week for 4 weeks on bilateral acupoints SP6, LR3, and CV4.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Integrative treatment including moxibustion therapy.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional treatment (watchful waiting or oral medication including α blocker, 5α-reductase inhibitors or antimuscarinic drugs).
Number of subjects: 60
Study: 22237557

Group type: EXPERIMENTAL
Intervention: Mediterranean-type diet with close dietetic supervision
Number of subjects: 90
Study: 21074214

Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19438082

Group type: EXPERIMENTAL
Intervention: Self-directed learning (SDL) kit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional instructor-led course
Number of subjects: 0
Study: 16503717

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate 200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topiramate
Number of subjects: 0
Study: 15523351

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 57

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 57
Study: 11422959

Group type: EXPERIMENTAL
Intervention: Iron supplementation on a weekly basis
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Anthelmintic treatment at the beginning and week 12
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Both iron supplementation and anthelmintic treatment
Number of subjects: 553

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: All three worms (Ascaris lumbricoides, Trichuris trichiura, hookworms)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Lower haemoglobin values and anaemia (< 120 g/l Hb)
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Taller women with greater arm circumference
Number of subjects: 553
Study: 9050126

Group type: EXPERIMENTAL
Intervention: 50% blockade of the bromocriptine GH response
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100% blockade of the bromocriptine GH response
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 10 ng/ml haloperidol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 100% blockade of the GH response
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8223165

Group type: EXPERIMENTAL
Intervention: Captopril (6.25mg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Captopril (12.5mg)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 3544626

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE) combined with low-dose heparin (LDH)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intermittent pneumatic calf compression (IPCC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intermittent pneumatic calf compression (IPCC) with graduated pressure stockings
Number of subjects: 114
Study: 28946789

Group type: EXPERIMENTAL
Intervention: Psychotherapy treatment for borderline personality disorder over four months
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Coping capacities
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Individualized treatments for personality disorders
Number of subjects: 8
Study: 29759590

Group type: EXPERIMENTAL
Intervention: MRI screening
Number of subjects: 8061
Study: 26615181

Group type: EXPERIMENTAL
Intervention: Sucrose analgesia
Number of subjects: 93

Group type: COMPARATOR
Intervention: Distilled water
Number of subjects: 93
Study: 24962666

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (1,000 mg calcium per day and 50,000 U vitamin D3 pearl twice during the study)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 21990519

Group type: EXPERIMENTAL
Intervention: Endovascular treatment with stenting
Number of subjects: 600

Group type: COMPARATOR
Intervention: Endovascular treatment without stenting
Number of subjects: 600
Study: 20113759

Group type: EXPERIMENTAL
Intervention: Interferential therapy with amplitude-modulated frequency (100Hz)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Interferential therapy without amplitude-modulated frequency (0Hz)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (with and without amplitude-modulated frequency)
Number of subjects: 46
Study: 16978739

Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg/kg
Number of subjects: 280

Group type: COMPARATOR
Intervention: Morphine 0.10 mg/kg
Number of subjects: 280
Study: 15957994

Group type: EXPERIMENTAL
Intervention: Intrapartum fentanyl (dose range 8-500 micrograms)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 425
Study: 11912393

Group type: EXPERIMENTAL
Intervention: Capsaicin (2 mM in 30 ml ethanol plus 70 ml 0.9% sodium chloride)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Resiniferatoxin (100 nM in 100 ml 0.9% sodium chloride)
Number of subjects: 24
Study: 9877147

Group type: EXPERIMENTAL
Intervention: ATHR (heart rate threshold)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AT4 (4 mmol x l(‐1) threshold)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IAT (individual anaerobic threshold)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prolonged exercise test (PET) at ATHR power output
Number of subjects: 10
Study: 8560416

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg intravenous infusion)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg intravenous infusion) in Group I patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg intravenous infusion) in Group II patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: DDAVP (0.3 microgram/kg intravenous infusion) in Group III patients
Number of subjects: 18
Study: 2617655

Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 81125

Group type: EXPERIMENTAL
Intervention: Gamma-globulin intramuscularly administered 24 hours after infection
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no gamma-globulin)
Number of subjects: 24
Study: 31862312

Group type: EXPERIMENTAL
Intervention: Single supra-therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 400/24/50 µg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Therapeutic inhaled dose of BDP/FF/GB pMDI (BDP/FF/GB 200/12/25 µg), twice daily for 7 consecutive days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Both groups (therapeutic and supra-therapeutic)
Number of subjects: 24
Study: 30690191

Group type: COMPARATOR
Intervention: Exercise with oral placebo (Group A)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Exercise with oral metformin (Group B)
Number of subjects: 66
Study: 26644202

Group type: EXPERIMENTAL
Intervention: GIK therapy
Number of subjects: 117
Study: 26116294

Group type: EXPERIMENTAL
Intervention: MRI-guided in-bore biopsy (IB-GB)
Number of subjects: 267

Group type: COMPARATOR
Intervention: MRI-ultrasound fusion-guided biopsy (FUS-GB) + transrectal ultrasound-guided biopsy (TRUS-GB)
Number of subjects: 267
Study: 23459854

Group type: EXPERIMENTAL
Intervention: Supervised resistance training program (8 exercises, 2 sets, 10-15 repetitions, 3 times/week)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Supervised stretching program (25-30 min/session, 2 times/week)
Number of subjects: 29
Study: 21303634

Group type: EXPERIMENTAL
Intervention: Subcutaneous bolus insulin injections once an hour
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Continuous intravenous insulin infusion
Number of subjects: 10
Study: 19394034

Group type: EXPERIMENTAL
Intervention: Insurance intervention
Number of subjects: 4070

Group type: COMPARATOR
Intervention: Delay in care
Number of subjects: 4070
Study: 16448552

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (1.5-6 g daily, orally t.i.d.)
Number of subjects: 20
Study: 15303786

Group type: EXPERIMENTAL
Intervention: Topical agent with occlusion (bioceramic-coated neoprene garment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical agent without occlusion
Number of subjects: 20
Study: 11550168

Group type: EXPERIMENTAL
Intervention: Genetic testing educational print materials
Number of subjects: 391

Group type: COMPARATOR
Intervention: General breast cancer education control materials
Number of subjects: 391
Study: 9257414

Group type: EXPERIMENTAL
Intervention: Intravenous vitamin D3 administration
Number of subjects: 0
Study: 8218671

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160/800 mg orally every 12 hours
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TMP-SMZ
Number of subjects: 42
Study: 3497990

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine (two doses, separated by two months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 100
Study: 30395145

Group type: EXPERIMENTAL
Intervention: Gain-framed message with anger emotion induction (mothers)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Gain-framed message with anger emotion induction (fathers)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Loss-framed message (not specified if anger or fear)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Gain-framed message with fear emotion induction (not specified if mothers or fathers)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Loss-framed message with fear emotion induction (not specified if mothers or fathers)
Number of subjects: 190
Study: 30058824

Group type: EXPERIMENTAL
Intervention: Mindfulness induction (body scan)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 53
Study: 27627981

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Liraglutide and Sitagliptin
Number of subjects: 52
Study: 23959713

Group type: EXPERIMENTAL
Intervention: Specific computerized training (ST), n=55
Number of subjects: 88

Group type: COMPARATOR
Intervention: Nonspecific computerized training (n-ST), n=33
Number of subjects: 88
Study: 23964461

Group type: EXPERIMENTAL
Intervention: Mirror neurons stimulation based VCD program practice at home
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 30
Study: 20569170

Group type: EXPERIMENTAL
Intervention: Non-surgical treatment with adjunctive dose of vitamin C (ChP1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment alone (ChP2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adjunctive vitamin C
Number of subjects: 60
Study: 17711908

Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide (CYC), calcineurine inhibitors (cyclosporine or tacrolimus), mycophenolate mofetil, azathioprine, rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment regimens including high doses of cyclophosphamide (CYC) and steroids
Number of subjects: 0
Study: 15289700

Group type: EXPERIMENTAL
Intervention: Agomelatine 25 mg/day
Number of subjects: 192

Group type: COMPARATOR
Intervention: Paroxetine 20 mg/day
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 11379805

Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg/day
Number of subjects: 138

Group type: COMPARATOR
Intervention: Sodium cromoglycate 60 mg/day
Number of subjects: 138
Study: 9225837

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy (2 IU/m2) for 12 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 7968874

Group type: EXPERIMENTAL
Intervention: Spirapril 6 mg once daily
Number of subjects: 49
Study: 3301500

Group type: EXPERIMENTAL
Intervention: Verapamil (V) 240 mg/die
Number of subjects: 54

Group type: COMPARATOR
Intervention: Chlorthalidone (C) 50 mg/die
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Verapamil (V) 240 mg/die + Chlorthalidone (C) 50 mg/die (V + C)
Number of subjects: 54
Study: 28851063

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT, n = 10)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Mindfulness program (MF, n = 9)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 28
Study: 27770114

Group type: EXPERIMENTAL
Intervention: Propofol mixed with 200mcg of phenylephrine
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Propofol mixed with 100mcg of phenylephrine
Number of subjects: 72

Group type: COMPARATOR
Intervention: Propofol mixed with normal saline
Number of subjects: 72
Study: 24822236

Group type: EXPERIMENTAL
Intervention: Prefabricated appliance (Relax)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Stabilization appliance
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 22116817

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) by 3 cycles of 5 minutes of arm ischemia/5 minutes of reperfusion
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (sham procedure)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 24
Study: 20858400

Group type: EXPERIMENTAL
Intervention: bimatoprost/timolol fixed combination
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 18499789

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MR angiography (CE-MRA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Digital subtraction angiography (DSA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Body remnants characterized by remnant protrusion into the coil mass
Number of subjects: 44
Study: 16641657

Group type: EXPERIMENTAL
Intervention: Involvement in decision-making (IDM) rated on a 5-point scale
Number of subjects: 0